![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Eli Lilly Begins Phase 3 Trial of Olumiant for COVID-19 Patients
Eli Lilly Begins Phase 3 Trial of Olumiant for COVID-19 Patients
![Eli Lilly logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Eli-Lilly-logo.gif?t=1616695830&width=430)
Eli Lilly has begun enrolling patients for a phase 3 trial of its rheumatoid arthritis treatment Olumiant (baricitinib) for hospitalized COVID-19 patients.
The trial will examine the proportion of patients treated with 4 mg of Olumiant who die or require ventilation by day 28 compared with those given a placebo.
Lilly said the study will complement other ongoing baricitinib trials in COVID-19 patients, included one being conducted by the National Institute of Allergy and Infectious Diseases.
Upcoming Events
-
21Oct